Since the beginning of the era of genome-wide association studies (GWAS), . 1200 human GWAS have now examined . 200 diseases and traits, and found almost 4000 single nucleotide polymorphism (SNP) associations. 1 This number is quite impressive, but up to now it is largely unknown how we can incorporate these findings into the clinical setting. One of the challenges for successful GWAS in the future will be to apply the findings in a way that accelerates drug and diagnostics development. This includes better integration of genetic studies into the drug development process and a focus on the role of genetic variation in maintaining health as a blueprint for designing new drugs and diagnostics. 2 To do so, we have to make a shift from intermediate phenotypes, such as systolic blood pressure, LDL-cholesterol levels, or C-reactive protein levels, to clinical outcomes such as coronary heart disease (CHD), myocardial infarction (MI), or diabetes. GWAS thus far have typically been designed to assess associations of millions of SNPs with only a single risk factor or disease. 3 However, since many cardiovascular risk factors and biomarkers are correlated and in combination contribute to disease and traits, it is hypothesized that genetic associations for risk factors and traits must be overlapping. 4 Thus, the question that has to be asked is whether SNPs associated with risk factors for clinical outcomes such as CHD or MI are also associated with the incidence of CHD and MI themselves, and vice versa.
This research question has been tested by the interesting paper by Angelakopoulou et al. of a large population-based study. 5 In their study, as depicted in Figure 1 , from the 14 SNPs associated with CHD risk in previously performed GWAS, only one SNP was associated with a risk factor for CHD, in this case (the obvious) LDL-cholesterol level. On the other hand, from the 23 SNPs associated with risk factors/biomarkers for CHD, only three SNPs were associated with the incidence of CHD. The explanation for the first finding given by the authors is that the effects of SNPs associated with CHD are mediated through unsuspected, as yet unknown, disease mechanisms. 6 Since with the GWAS we have more information available regarding which genetic variation determines the intermediate phenotypes, it is much easier to execute these Mendelian randomization studies.
With Mendelian randomization studies it has already been 'proven' that C-reactive protein levels are probably not causally related to cardiovascular disease, but are merely a risk indicator. 7 Another nice example of a Mendelian randomization study is the investigation of the relationship between plasma cholesterol levels and cancer risk using the ApoE genotype. 8 In contrast to what many assumed, these findings suggested that low levels of cholesterol are not causally related to an increased risk of cancer and that treatment with cholesterol-lowering agents does not increase cancer risk. A sudden drop in plasma cholesterol levels can therefore be predictive for an underlying tumour. Hence, in clinical practice, more attention could possibly be paid to sudden drops in cholesterol levels as a predictor of cancer. Lately, more and more GWAS have investigated pharmacogenetics of various treatments and outcomes. 9 The link with clinical practice in these studies is clear; however, up to now the results of these studies have been inconsistent in most fields. Pharmacogenetic GWAS can best be performed in randomized placebo-controlled clinical trials with large study populations, needing international collaboration. An example of such effort is the GIST consortium, set up with a boost from the EU-KP7 PHASE programme, 10 in which eight randomized controlled clinical trials perform a pharmacogenetics analysis to investigate which genetic variations are responsible for the differential effect of statins on LDL lowering. These currently ongoing GWAS in large study populations have the promise to provide more convincing evidence. This offers enough reasons to remain optimistic that, even though only with small steps at a time, we are heading towards an era where we can finally use pharmacogenetics as a prescribing tool as part of clinical practice aiming at optimizing treatment for the individual patient.
In conclusion, GWAS have reported on many SNP associations with various traits and diseases. Although these numbers are quite impressive, we still have to carry out a lot of additional research to find the mechanisms underlying diseases and to build a bridge to a clinical setting. To bring genetics closer to clinical practice, we have to (i) perform additional fine mapping and functional studies to identify and understand the novel pathways in disease mechanisms; (ii) perform Mendelian randomization studies to deal with problems of causal inference and confounding in observational studies; and (iii) perform pharmacogenetic analysis in randomized placebo-controlled clinical trials with large study populations. Carrying the genetic markers for risk factors for a disease is not yet the same as developing the disease; however, we may still have great expectations for unravelling the pathophysiology in this regard.
Conflicts of interest: none declared. Figure 1 Number of SNPs that were previously found to be associated with CHD risk or risk factors of CHD that are now associated in the comparative analysis by Angelakopoulou et al. 5 Left panel: from the 14 SNPs found in the literature to be associated with CHD risk, nine were replicated to be associated with CHD risk in the study of Angelakopoulou et al.; only one was also associated with risk factors for CHD in the comparative analysis. Right panel: from the 23 SNPs found in the literature to be associated with CHD risk factors, 18 were replicated to be associated with risk factors in the study of Angelakopoulou et al.; three of those were also associated with CHD risk in the comparative analysis.
